Angel Cobo, PhD

About Angel

Angel is a scientist and strategic operator working at the intersection of drug development, biotechnology, and investment.

In his current role, he leads early-stage drug development programs from target validation through IND-enabling studies and NewCo formation. Angel works with investigators, founders, clinicians, and KOLs to pressure-test therapeutic hypotheses, identify critical risks, and design development strategies that generate clear, decision-enabling data.

His background in chemistry, pharmacology, and venture investing allows him to evaluate programs from both a scientific and a commercial perspective. He assesses mechanisms, competitive landscapes, translational strategies, development risks, and capital requirements with a focus on improving probability of technical success and establishing meaningful clinical differentiation.

What draws Angel most is elegant chemistry, novel mechanisms of action, and emerging biotechnology platforms with the potential to address difficult unmet medical needs. His mission is to work with teams that push scientific boundaries, translate rigorous research into medicines, and build companies that create real value for patients and the biotechnology ecosystem.